Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations

被引：46
|
作者：
Coulson, A. [1 ]
Levy, A. [1 ]
Gossell-Williams, M. [1 ]
机构：
[1] Univ W Indies, Dept Basic Med Sci, Pharmacol Sect, Kingston 7, Jamaica
来源：
WEST INDIAN MEDICAL JOURNAL | 2014年 / 63卷 / 06期
关键词：
Antigenic targets; cancer therapy; clinical benefits; monoclonal antibodies; CHRONIC LYMPHOCYTIC-LEUKEMIA; BRENTUXIMAB VEDOTIN; COLORECTAL-CANCER; LYMPHOMA; RITUXIMAB; CHEMOTHERAPY; RADIOIMMUNOTHERAPY; TRASTUZUMAB; BEVACIZUMAB; INDUCTION;
D O I：
10.7727/wimj.2013.241
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Rituximab was the first chemotherapeutic monoclonal antibody (CmAb) approved for clinical use in cancer therapeutics in 1997 and has significantly improved the clinical outcomes in non-Hodgkin's lymphoma. Since then, numerous CmAbs have been developed and approved for the treatment of various haematologic and solid human cancers. In this review, the classification, efficacy and significantly reduced toxicity of CmAbs available for use in the United States of America are presented. Finally, the limitations of CmAbs and future considerations are explored.
引用
收藏
页码：650 / 654
页数：5
相关论文
共 50 条
  • [1] Monoclonal antibodies for the therapy of cancer
    Andrew Simpson
    Otavia Caballero
    BMC Proceedings, 8 (Suppl 4)
  • [2] Trial watch Monoclonal antibodies in cancer therapy
    Vacchelli, Erika
    Eggermont, Alexander
    Galon, Jerome
    Sautes-Fridman, Catherine
    Zitvogel, Laurence
    Kroemer, Guido
    Galluzzi, Lorenzo
    ONCOIMMUNOLOGY, 2013, 2 (01):
  • [3] Trial Watch Tumor-targeting monoclonal antibodies in cancer therapy
    Vacchelli, Erika
    Aranda, Fernando
    Eggermont, Alexander
    Galon, Jerome
    Sautes-Fridman, Catherine
    Zitvogel, Laurence
    Kroemer, Guido
    Galluzzi, Lorenzo
    ONCOIMMUNOLOGY, 2014, 3 (01):
  • [4] Mechanisms of Action and Limitations of Monoclonal Antibodies and Single Chain Fragment Variable (scFv) in the Treatment of Cancer
    Rodriguez-Nava, Cynthia
    Ortuno-Pineda, Carlos
    Illades-Aguiar, Berenice
    Flores-Alfaro, Eugenia
    Leyva-Vazquez, Marco Antonio
    Parra-Rojas, Isela
    del Moral-Hernandez, Oscar
    Vences-Velazquez, Amalia
    Cortes-Sarabia, Karen
    del Carmen Alarcon-Romero, Luz
    BIOMEDICINES, 2023, 11 (06)
  • [5] Successes and Limitations of Targeted Cancer Therapy in Lung Cancer
    Suda, Kenichi
    Mitsudomi, Tetsuya
    SUCCESSES AND LIMITATIONS OF TARGETED CANCER THERAPY, 2014, 41 : 62 - 77
  • [6] Successes and Limitations of Targeted Cancer Therapy in Breast Cancer
    Curigliano, Giuseppe
    Criscitiello, Carmen
    SUCCESSES AND LIMITATIONS OF TARGETED CANCER THERAPY, 2014, 41 : 15 - 35
  • [7] Successes and Limitations of Targeted Cancer Therapy in Colon Cancer
    Koehne, Claus-Henning
    SUCCESSES AND LIMITATIONS OF TARGETED CANCER THERAPY, 2014, 41 : 36 - 50
  • [8] Overview of monoclonal antibodies in cancer therapy: present and promise
    Stern, M
    Herrmann, R
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005, 54 (01) : 11 - 29
  • [9] Therapeutic antibodies: successes, limitations and hopes for the future
    Chames, Patrick
    Van Regenmortel, Marc
    Weiss, Etienne
    Baty, Daniel
    BRITISH JOURNAL OF PHARMACOLOGY, 2009, 157 (02) : 220 - 233
  • [10] The development of monoclonal antibodies for the therapy of cancer
    Farah, RA
    Clinchy, B
    Herrera, L
    Vitetta, ES
    CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 1998, 8 (3-4): : 321 - 356
12345